Clostridium difficile infection among hematopoietic stem cell transplant recipients: Beyond colitis

Current Opinion in Infectious Diseases

Volumn 26, Issue 4, 2013, Pages 326-331

  Alonso, Carolyn D ^a   Marr, Kieren A ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; colitis; graft versus host disease; hematopoietic stem cell transplant

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ALLOIMMUNITY; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION CONTROL; NONHUMAN; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; VULNERABLE POPULATION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RISK FACTORS;

EID: 84879879355     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283630c4c     Document Type: Review

References (52)

1. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: Statistical Brief #124. Rockville, MD: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs; 2006.
2. Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61:157-162.
3. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012; 55:216-223.
4. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441. (Pubitemid 41770164)
5. Kamboj M, Son C, Cantu S, et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol 2012; 33:1162-1165.
6. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-1084. (Pubitemid 41338761)
7. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449. (Pubitemid 41770165)
8. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13:97-101. (Pubitemid 15030800)
9. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-397. (Pubitemid 30084537)
10. Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bonemarrow- transplant recipients. N Engl J Med 1982; 306:1010-1012.
11. Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994; 107: 1398-1407. (Pubitemid 24328277)
12. LewMA, Kehoe K, Ritz J, et al. Ciprofloxacin versus trimethoprim/ sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13:239-250.
13. Mossad SB, Longworth DL, Goormastic M, et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18:265-271. (Pubitemid 26283673)
14. Yuen KY, Woo PC, Liang RH, et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis 1998; 30:75-81. (Pubitemid 28102860)
15. Bilgrami S, Feingold JM, Dorsky D, et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23:1039-1042. (Pubitemid 29250849)
16. Leger CS, Bredeson C, Kearns B, et al. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6 (2A):204-210.
17. Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graftversus- host disease and nonrelapse mortality. Bone Marrow Transplant 2000; 26:871-876.
18. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001; 32:391-395. (Pubitemid 32173624)
19. Toor AA, van Burik JA, Weisdorf DJ. Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 2001; 28:1129-1134. (Pubitemid 34082968)
20. Gorschluter M, Glasmacher A, Hahn C, et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33:786-791. (Pubitemid 32831834)
21. Kang G, Srivastava A, Pulimood AB, et al. Etiology of diarrhea in patients undergoing allogeneic bone marrow transplantation in South India. Transplantation 2002; 73:1247-1251. (Pubitemid 34454270)
22. Altclas J, Requejo A, Jaimovich G, et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2002; 34:723. (Pubitemid 34165344)
23. Leung S, Metzger BS, Currie BP. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol 2010; 31:313-315.
24. Therriault BL, Wilson JW, Barreto JN, Estes LL. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc 2010; 85:711-718.
25. Dubberke ER, Reske KA, Srivastava A, et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010; 24:192-198.
26. Chopra T, Chandrasekar P, Salimnia H, et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011; 25:E82-E87.
27. Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012; 18:1295-1301.
28. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54:1053-1063.
29. Trifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficileassociated disease during stem cell transplantation. Biol Blood Marrow Transplant 2012.
30. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
31. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-1703.
32. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351:633-636. (Pubitemid 28098446)
33. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-536.
34. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009; 44:74-78.
35. Wang MS, Evans CT, Rodriguez T, et al. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol 2013; 34:127-132.
36. Dubberke ER, Sadhu J, Gatti R, et al. Severity of Clostridium difficileassociated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol 2007; 28:208-211. (Pubitemid 46374164)
37. Terada Y, Onishi Y, Kim S, et al. Clinical significance of positive Clostridium difficile (CD) toxin in the stool of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2004; 104:353B-B.
38. Bauer MP, Kuijper EJ, van Dissel JT, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15:1067-1079.
39. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55:905-914.
40. Van der Velden WJ, Netea MG, de Haan AF, et al. Role of the mycobiome in human acute graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19:329-332.
41. Murphy S, Nguyen VH. Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma 2011; 52:1844-1856.
42. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-472. (Pubitemid 39179608)
43. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-1597. (Pubitemid 40720808)
44. Cornely OA, Miller M, Fantin B, et al. Clinical outcomes for cancer patients with Clostridium difficile infection (CDI). Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases March 31-April 3 2012; 40, London, UK.
45. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31:995-1000. (Pubitemid 32299359)
46. Optimer Pharmaceuticals. A phase 3b multi-center, double-blind, randomized, placebo controlled study to demonstrate the safety and efficacy of fidaxomicin for prophylaxis against Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000-2013. Available from http://clinicaltrials.gov/ct2/show/NCT01691248. NLM Identifier: NCT01691248.
47. Murphy S, Nguyen VH. Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma 2011; 52:1844-1856.
48. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-472. (Pubitemid 39179608)
49. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-1597. (Pubitemid 40720808)
50. Cornely OA, Miller M, Fantin B, et al. Clinical outcomes for cancer patients with Clostridium difficile infection (CDI). Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases March 31-April 3 2012; 40, London, UK.
51. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31:995-1000. (Pubitemid 32299359)
52. Optimer Pharmaceuticals. A phase 3b multi-center, double-blind, randomized, placebo controlled study to demonstrate the safety and efficacy of fidaxomicin for prophylaxis against Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000-2013. Available from http://clinicaltrials.gov/ct2/show/NCT01691248. NLM Identifier: NCT01691248.